Table 3 –

Descriptive postoperative characteristics of patients related to salvage lymph node dissection (sLND).

Variable	Overall population (n = 189; 100%)
Surgical approach, n (%)
Open	183 (97)
Laparoscopic	6 (3)
Lymph nodes removed at sLND	19 (12, 35)
Positive nodes at sLND, n (%)
0	40 (21)
1	33 (17)
2	18 (10)
≥3	98 (52)
PSA level after sLND (ng/mL)	0.6 (0.0, 2.0)
PSA response (<0.2 ng/mL) after sLND, n (%)
No	120 (63)
Yes	69 (37)
Post-sLND complications, n (%)
Clavien-Dindo ≤1	137 (72)
Clavien-Dindo ≥2	25 (13)
Unknown	27 (14)
Additional therapies after sLND
None	14
ADT alone	81
RT alone	18
ADT + RT	29
ADT + CT	6
ADT + RT + CT	11
Other combinations	30
ADT administration within 6 mo from sLND, n (%)
No	74 (39)
Yes	115 (61)
RT administration within 6 mo from sLND, n (%)
No	166 (88)
Yes	23 (12)

ADT = androgen deprivation therapy; CT = chemotherapy; PSA = prostate-specific antigen; RT = radiation therapy.

All numbers are medians (interquartile range) and frequencies (proportions).